What is Acesion Pharma?
Acesion Pharma is a biopharmaceutical company dedicated to the development of innovative therapies for the safe and effective treatment of atrial fibrillation, the most prevalent form of cardiac arrhythmia. The company's core strategy revolves around pioneering SK ion channel inhibition, a novel mechanism designed to enhance treatment efficacy and patient safety. By building a robust pipeline of best-in-class potential therapies, Acesion Pharma aims to significantly improve patient outcomes for those affected by this common cardiac condition. Their target clientele includes healthcare providers and patients seeking advanced treatment options.
How much funding has Acesion Pharma raised?
Acesion Pharma has raised a total of $59.5M across 3 funding rounds:
Private Equity
$2.5M
Series A
$10M
Series B
$47M
Private Equity (2014): $2.5M with participation from Novo Seeds and Broadview Ventures
Series A (2016): $10M led by The Wellcome Trust and Novo A/S
Series B (2023): $47M supported by Alpha Wave Global, Global BioAccess Fund, Canaan, and Novo Holdings
Key Investors in Acesion Pharma
The Wellcome Trust
The Wellcome Trust is an independent global charitable foundation supporting discovery research and tackling urgent health challenges through grants, partnerships, and advocacy.
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments in the life sciences sector.
Canaan
Canaan Inc. is a technology company known for designing and manufacturing high-performance computing chips and mining equipment, with potential interests in related technology sectors.
What's next for Acesion Pharma?
The recent major strategic investment in Acesion Pharma's Series B round indicates a strong validation of their innovative approach to treating atrial fibrillation. This significant capital infusion is expected to accelerate the advancement of their pipeline, potentially moving their SK ion channel inhibitors closer to clinical trials and eventual market entry. The company's focus on a novel mechanism of action positions it to address unmet needs in a large patient population, suggesting a future emphasis on scaling operations, expanding research and development efforts, and potentially forging strategic partnerships to bring their therapies to a global market.
See full Acesion Pharma company page
